Video

Dr. Tolaney on Activity With Abemaciclib in Patients With HR+/HER2- Breast Cancer

Author(s):

Sara M. Tolaney, MD, MPH
Conference|ASCO Annual Meeting

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses the results of a phase II trial exploring the efficacy of abemaciclib as a treatment of brain metastases that are secondary in patients with hormone receptor (HR)-positive,HER2-negative breast cancer.

<<<

View more from the 2017 ASCO Annual Meeting

Related Videos
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
Yuan Yuan, MD, PhD
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Paolo Tarantino, MD
Yuan Yuan, MD, PhD
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Related Content
Elacestrant plus abemaciclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
September 18th 2024

Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Anna Dańska-Bidzińska, MD, a gynecologist from Warsaw Medical University in Warsaw, Poland
September 18th 2024

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com
September 17th 2024

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Xinan Sheng, MD, of Peking University Cancer Hospital and Institute
September 17th 2024

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC